Social science & medicine (1982)
February 1, 2026
Sarah Kratina, Carol Strike, Robert Schwartz et al.
Psychedelic substances are recognized for their potential to ease psychological suffering linked to end-of-life issues, yet policy remains restrictive. The wide range of both substances and therapeutic approaches used in end-of-life populations has not been adequately covered by reviews to date. To identify and learn from the variety that exists within the research on therapeutic psychedelic...
Politics & Policy
January 24, 2026
Sarah Kratina, Robert Schwartz, Carol Strike et al.
2 citations
ABSTRACT Psychedelic interventions are not publicly available through Canada's healthcare system. Despite growing scientific evidence, public interest, and efforts to expand access to psychedelic therapies for end‐of‐life psychological suffering, Canadian policies remain restrictive. Efforts are underway to expand access, but knowledge gaps exist regarding the policy landscape in Canada. This...
PLoS One
2025
Sarah Kratina, Carol Strike, Robert Schwartz et al.
1 citation
Psychedelic substances are increasingly recognized for their therapeutic potential to ease psychological suffering linked to end-of-life issues. However, amid renewed scientific and public interest, policy remains restrictive. Existing reviews have made progress in synthesizing the results of studies of psychedelic interventions, especially psilocybin, and particularly with regard to their...
Psychedelic medicine (New Rochelle, N.Y.)
June 1, 2024
Ryan Yermus, John Bottos, Nathan Bryson et al.
13 citations
Ketamine-assisted psychotherapy (KAP) is an emerging treatment option to alleviate treatment-resistant affective disorders, but its long-term effectiveness remains unclear. To examine the treatment effects of KAP on anxiety, depression, and post-traumatic stress disorder (PTSD) at 1, 3, and 6 months post-treatment. This retrospective effectiveness study included self-reported outcomes from...